News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amazon Biotech Announces Appointment of New CEO and New Corporate Counsel


5/21/2008 2:55:41 PM

NEW YORK, NY--(Marketwire - May 21, 2008) - Amazon Biotech, Inc. (OTCBB: AMZO) (FRANKFURT: B2DA) announced that Mr. Eliyahu BenTal Tolchinsky has been appointed as director and Chief Executive Officer of the Company.

Mr. Tolchinsky, a graduate of Cornell University and Tulane Law School, has a strong background in Research and Development, intellectual property protection and regulatory compliance. Mr. Tolchinsky has been employed by the patent department of Webb & Associates in Rechovot, Israel, the R&D department of Mazal Pharmaceuticals, Inc., Hadassah Ein Kerem Hospital, Jerusalem, Israel, R.A.M. Technologies, Jerusalem, Israel, and Halsey Group Consultants in New Jersey.

Mr. Tolchinsky said, "I am excited to join Amazon Biotech and I look forward to updating the shareholders with positive news."

Amazon Biotech's new corporate counsel is Stephen M. Fleming, Law Offices of Stephen M. Fleming PLLC, 110 Wall Street, 11th Floor, New York, New York 10005, Phone 516-833-5034.

Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future with the goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials or enter the FDA Fast Track program to reach the marketplace. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.

Contact:

LC Group Rick Lutz (404) 261-1196


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES